Safety and Effectiveness of Adding Saquinavir (FORTOVASE) in Soft Gel Capsule Form to an Anti-HIV Drug Combination in HIV-Infected Patients
- Conditions
- HIV Infections
- Registration Number
- NCT00002229
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
The purpose of this study is to see if it is safe and effective to give saquinavir (as a soft gel capsule taken by mouth) along with 2 other anti-HIV drugs to HIV-infected patients.
- Detailed Description
Prior to initiation of study treatment all patients are screened and baseline lab values are taken. Patients then receive the study treatment, FORTOVASE, two times a day plus 2 new NRTI's. Assessments will be performed at specified intervals throughout the duration of treatment.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 80
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (22)
ASC Inc
🇺🇸Hobson City, Alabama, United States
Dean Martin
🇺🇸Phoenix, Arizona, United States
Wilbert Jordan
🇺🇸Paramount, California, United States
Whitman Walker Clinic
🇺🇸Washington, District of Columbia, United States
Duval County Health Department
🇺🇸Jacksonville, Florida, United States
Ctr for Quality Care
🇺🇸Tampa, Florida, United States
NTouch Research Corp
🇺🇸Decatur, Georgia, United States
Univ of Illinois Hosp at Chicago
🇺🇸Chicago, Illinois, United States
Univ of Kentucky
🇺🇸Lexington, Kentucky, United States
C100 HIV Outpatient Program
🇺🇸New Orleans, Louisiana, United States
Scroll for more (12 remaining)ASC Inc🇺🇸Hobson City, Alabama, United States